Project Grant 2136542
Award Date
3/1/22
Completion Date
2/28/23
Dollars Obligated
$256K
Federal Agency
National Science Foundation
Awardee
Nostopharma LLC (FKVPNPQK64H8)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Halethorpe, MD 21227, USA
Similar Awards
This National Science Foundation (NSF) Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,016,000 in funding to Nostopharma LLC to develop an innovative, sustained-release, and biodegradable drug delivery platform for localized treatment of post-traumatic injuries. The goal is to create a medication delivery system using anti-inflammatory nanoparticles embedded with a Hedgehog pathway antagonist, arsenic trioxide, to address unmet...
Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...
Nano Pharmasolutions, Inc. received a $275,961 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant funds the development of a novel nanoformulation drug delivery platform to address challenges associated with poorly soluble drugs. The goal is to improve drug solubility and bioavailability through innovative formulation approaches. The one-year project period runs from August 1, 2021...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award to Reselute, Inc. provides $998,921 to develop a novel implantable orthopedic medical device and procedure to reduce recovery duration and infection risks associated with severe traumatic fractures of the long bones. The project aims to advance a 3D-printed, antibiotic-releasing intramedullary nail to improve upon current standard-of-care implants that are prone to...
This National Science Foundation (NSF) SBIR Phase I Project Grant awarded to Eascra Biotech, Inc. is focused on developing and advancing regulatory pathways for space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The $274,990 award, granted on December 15, 2024, aims to demonstrate the comparability of space-manufactured JBNPs to earth-made counterparts, with the goal of revolutionizing cancer treatment by providing a versatile and more...
This National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I project aims to develop a novel, minimally invasive, bioabsorbable, steroid-eluting suture and surgical implant procedure to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists. The $255,045 award, granted on September 15, 2023 under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, will fund the formulation of dissolvable polymers,...
This Project Grant award of $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will support the development of a novel mammalian cell-based nano-biological coating for implantable medical devices at Novaurum Biosciences Incorporated in Somerville, MA. The project aims to address the critical issue of implant-related infections, which cost the U.S. healthcare system over $8.6 billion annually, by creating a biocompatible and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Technology Transfer (STTR) project grant, awarded to Vivosphere LLC, is developing a novel 3D tissue-engineered platform for cancer modeling and high-throughput drug screening. The $275,000 project aims to create a more physiologically relevant and scalable system to improve the translation of preclinical cancer drug candidates to clinical trials. Key objectives include testing...
Biosapien Inc. received a $256,000 Project Grant award from the National Science Foundation on May 1, 2021 to develop a novel 3D printed biodegradable mesh delivering active pharmaceutical ingredients in a sustained and localized manner under the Small Business Innovation Research Phase I program. The SBIR Phase I grant supports the proof-of-concept stage of developing Biosapien's technology, with the work expected to be completed by June 30, 2022. The NSF Technology, Innovation, and...
This Project Grant award of $305,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of an advanced wound care product for treating diabetic foot ulcers. The product is a microneedle bandage that delivers three therapeutic agents to disinfect the wound, prevent bacterial biofilm re-formation, and activate the immune system to facilitate healing. Initial work will be conducted using skin tissue cultures and testing...